Liverpool ready to enter fresh contract talks to KEEP star at Anfield
According to a new report from GIVEMESPORT, Arne Slot's side are preparing to re-enter negotiations with the Colombian's representatives in order to keep the winger at Anfield long-term.
Advertisement
Contract negotiations had taken place earlier in the season but appeared to reach a stalemate, and at one point earlier in the campaign it looked as though Diaz was almost certain to move to Barcelona this summer.
Issues around the player's wage demands may have been what halted negotiations previously, with the 28-year-old looking to significantly increase his current salary.
Still on the same deal he signed when he joined from Porto in 2022, Diaz reportedly earns considerably less than his teammates who make up the rest of Liverpool's attack.
Liverpool's change of heart
Diaz started the season in sensational form, scoring five in five and asserting himself as one of the main goal threats in Slot's side, but his output slowed from that point.
Advertisement
Between 28 September and 12 February Diaz was involved in 18 Premier League games but only managed to score three and assist two in this time.
This dry spell led to many accepting that Diaz's time in Merseyside was probably going to come to an end this summer, but he has managed to turn his form around in the closing weeks of the season.
Eight goal involvements in his last 10 league matches appear to have been enough for the Anfield hierarchy to decide they want Diaz to remain a Red, not just for next season but for the foreseeable future.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Atalanta look at the Premier League for Mateo Retegui replacements
Mateo Retegui was the Serie A top scorer last season but he has already left Atalanta to move to Al Qadsiya in the Saudi Pro League. Atalanta have since been looking at replacements, to fill the hole left in the striker position. As per their latest targets are from the Premier League – Rodrigo Muniz of Fulham and Jean Phillipe Mateta of Crystal Palace. The promising Brazilian Muniz has scored 17 goals in the last two seasons in the Premier League and is definitely someone who can develop going forward. Newcastle United are also interested in him. Mateta, on the other hand, is in his peak and has become one of the Premier League's best strikers. He fired Crystal Palace to the FA Cup last season and Manchester United is said to be an interested party as well. Neither of these players will come cheap however and any possible deal is expected to be financed by Ademola Lookman's exit, which seems to be approaching. Kaulik Mitra | GIFN
Yahoo
28 minutes ago
- Yahoo
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci's successful molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci. The collaboration, originally announced in November 2023, combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to accelerate the development of novel and breakthrough therapeutics for chronic and debilitating skin diseases. 'Using advanced AI capabilities to design therapeutic candidates against historically challenging disease targets is a highly promising approach and Absci´s de-novo AI platform capabilities have already demonstrated early success' said Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall. 'We are pleased to expand our collaboration as we continue to harness AI to help us develop innovative treatments for patients living with severe skin conditions.' Under the terms of the collaboration, Absci is leveraging its generative AI platform combined with its wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development programs of those candidates. Absci is eligible to receive up to approximately $650 million in upfront, R&D, and post-approval milestone payments across both programs, plus royalties on potential product sales. 'The progress in our collaboration is a testament that AI de novo drug design is a successful approach to unlock novel biology where traditional drug discovery approaches have failed,' said Sean McClain, Founder and CEO of Absci. 'We're proud of this milestone and excited to deepen our collaboration with Almirall with the goal of bringing a new generation of AI-created therapeutics for dermatology patients.' The expansion of the collaboration to include a second program is at the heart of the shared commitment of both companies - to accelerate innovation in dermatology by using generative AI to enable new therapeutic approaches. About Almirall Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. For more information, please visit Corporate Communications: Investor Relations Phone: +34 93 291 35 08 Phone: (+34) 93 291 30 87 About Absci Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube. Absci Media Contactpress@ Absci Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@
Yahoo
28 minutes ago
- Yahoo
Report: Premier League and European clubs target Chelsea striker
Chelsea Transfer Talk: Nicolas Jackson's Future Uncertain Amid Simons Pursuit Jackson's Chelsea Status No Longer Secure Chelsea are reportedly bracing for fresh interest in Nicolas Jackson following Benjamin Sesko's departure from RB Leipzig. According to Sky Sports' Kaveh Solhekol, 'Chelsea are expecting there to be renewed interest in Nicolas Jackson in the next few days after RB Leipzig sell Benjamin Sesko.' Interest is said to be coming from Champions League-level clubs across Italy, Germany and the Premier League. It's a significant development for the 23-year-old Senegalese striker, who managed 14 goals in all competitions last season. Despite his starting spot, Jackson is 'not viewed as untouchable at Chelsea' following the arrivals of Liam Delap and Joao Pedro. That sentiment marks a major shift in the club's forward planning — and perhaps hints at evolving tactical preferences under Enzo Maresca. Transfer Market Shaping Jackson's Valuation With striker valuations climbing, Jackson's price tag would 'be in line with fees paid for strikers in the current market,' reports Sky Sports. While no official number was shared, Chelsea will likely seek a premium for a young, developing player with Champions League experience. His form was patchy in 2024/25, but Chelsea are aware that young forwards often need time to mature. Letting Jackson go so early could risk repeating mistakes of past sales like Romelu Lukaku or Mo Salah. Simons on Chelsea's Radar Parallel to Jackson's future, Chelsea are targeting a move for Dutch star Xavi Simons. They are reportedly hoping to secure a deal for under £50 million. 'They value the RB Leipzig player at between €50m and €55m,' according to Sky Sports. Photo IMAGO Simons impressed on loan at Leipzig last season, and his versatility in midfield or wide roles fits Chelsea's long-term rebuild. However, it's worth noting: 'Chelsea have not made a bid for Simons yet.' That might change soon as the end of the transfer window nears. Our View – EPL Index Analysis From a Chelsea fan's perspective, this update raises mixed emotions. On one hand, Nicolas Jackson's inconsistency last season did frustrate large sections of the fanbase — especially in tight games where composure in front of goal was lacking. But on the other, he showed promise, work rate, and glimpses of genuine quality. If Chelsea choose to cash in now, the key question becomes: is Joao Pedro or Liam Delap ready to lead the line in the Premier League? Joao Pedro offers flair and flexibility, but lacks a traditional No.9 profile, while Delap is still very raw. Jackson, for all his flaws, is further along in his development. The Simons news is exciting. Chelsea have lacked creativity and ball-carrying midfielders who can transition quickly and affect the final third. Xavi Simons ticks those boxes, and if the board can secure him for under £50m, it would represent smart business.
